ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Tumor necrosis factor (TNF)"

  • Abstract Number: 0927 • ACR Convergence 2023

    A Complex Interplay Among Gut Lachnoclostidium, HLA Haplotype DRB1*07:01, and the TNF Superfamily in Anti-Ro+ Women with a Spectrum of Preclinical and Clinical Autoimmunity Whose Children Have Neonatal Lupus

    Robert Clancy1, Caroline Izmirly1, Miranda Marion2, Nicola Fraser1, Joel Guthridge3, Timothy Howard2, Peter Izmirly4, Mala Masson5, Jill Buyon1, Judith James3 and Carl Langefeld6, 1NYU Grossman School of Medicine, New York, NY, 2Wake Forest University, Winston-Salem, NC, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4New York University School of Medicine, New York, NY, 5New York University, New York, NY, 6Wake Forest University School of Medicine, Winston-Salem, NC

    Background/Purpose: Mothers of children with neonatal lupus (NL) are often clinically asymptomatic or have insufficient criteria for a formal rheumatologic diagnosis, despite having high titers…
  • Abstract Number: 0979 • ACR Convergence 2023

    Use and Discontinuation of Tumour Necrosis Factor Inhibitors Among Pregnant Women with Chronic Inflammatory Diseases

    Leah K. Flatman1, Sasha Bernatsky2, Isabelle Malhamé3, Yvan St. Pierre2, Olga Basso1, Anick Bérard4 and Evelyne Vinet5, 1McGill University, Montreal, QC, Canada, 2Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 3McGill University Health Centre, Montreal, QC, Canada, 4University of Montreal, Montreal, QC, Canada, 5McGill University Health Centre, Montréal, QC, Canada

    Background/Purpose: Early consensus statements recommended discontinuing tumour necrosis factor inhibitors (TNFi) during pregnancy. Despite new guidelines recommending against this, the choice to stop TNFi pre-conception…
  • Abstract Number: 1073 • ACR Convergence 2023

    Risk of Inflammatory Central Nervous System Diseases Among New Users of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs

    Maximilian Casey1, Sonia Pannu2, Saffia Bajwa3, Ali Duarte-Garcia4 and Mike Putman5, 1Medical College of Wisconsin, Milwaukee, WI, 2University School of Milwaukee, River Hills, WI, 3Medical College of Wisconsin, Wauwatosa, WI, 4Mayo Clinic, Rochester, MN, 5Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI

    Background/Purpose: Inflammatory and demyelinating central nervous system (CNS) adverse events have been observed among new users of tumor necrosis factor (TNF) inhibitors. No studies to…
  • Abstract Number: 1333 • ACR Convergence 2023

    Rheumatoid Arthritis-associated Lymphoproliferative Disorders: A Multi-center Analysis of Clinical Outcomes and Evaluation of Anti-rheumatic Drugs After LPD Onset

    YOSHIHIKO HOSHIDA1, Atsuko Tsujii2, SHIRO OHSHIMA3, YUKIHIKO SAEKI3, MASATO YAGITA4, TOMOYA MIYAMURA5, Masao Katayama6, TOMONORI KAWASAKI7, YASUSHI HIRAMATSU8, Hisaji Oshima9, TOSHIHIKO MURAYAMA10, SHINJI HIGA11, KAZUYA KURAOKA12, FUMINORI HIRANO13, KENJI ICHIKAWA14, MITSUTOSHI KUROSAWA15, HIROAKI SUZUKI15, NORIYUKI CHIBA16, TAKAO SUGIYAMA17, YUKO MINAMI18, HITOSHI NIINO19, ATSUSHI IHATA20, IKUO SAITO21, AKIKO MITSUO22, TOSHITAKA MAEJIMA23, ATSUHIRO KAWASHIMA24, HIROSHI TSUTANI25, KOICHIRO TAKAHI26, TAKAHIKO KASAI27, YOKO SHINNO28, YOSHIRO TACHIYAMA29, NORIHIRO TERAMOTO30, KENICHI TAGUCHI31, SHINJI NAITO32, SHIGERU YOSHIZAWA33, MASAHIRO ITO34, YASUO SUENAGA35, Shunsuke Mori36, SHOICHI NAGAKURA37, NORIE YOSHIKAWA38, MITSUHARU NOMOTO39, ATSUHISA UEDA40, SHOUHEI NAGAOKA41, YUKIO TSUURA42, KEIGO SETOGUCHI43, SHOJI SUGII44, Asami Abe45, TOSHIAKI SUGAYA46, HIROYUKI SUGAHARA47, MASAHIRO KOSETO48, YASUO KUNUGIZA2, NORISHIGE IIZUKA3, RYOSUKE YOSHIHARA4, HIROKI YABE5, TOMOAKI FUJISAKI6, EIICHI MORII7, MORISHIGE TAKESHITA8, MASAKAZU SATO9, KAZUYOSHI SAITO10, Kiyoshi Matsui11, YASUHIKO TOMITA12, HIROSHI FURUKAWA13 and Shigeto Tohma14, 1National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan, 2Osaka Minami Medical Center, Kawachinagano City, Japan, 3National Hospital Organization (NHO), Osaka Minami Medical Center, Kawachinagano, Japan, 4Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-kofukai, Osaka, Japan, 5NHO Kyushu Medical Center, Fukuoka, Japan, 6National Hospital Organization, Nagoya Medical Center, Nagoya, JP, Nagoya, Japan, 7NHO Nagoya Medical Center, Nagoya, Japan, 8Japanese Red Cross Society Himeji Hospital, Himeji, Japan, 9National Tokyo Medical Center, Tokyo, Japan, 10NHO Kumamoto Medical Center, Kumamoto, Japan, 11Daini Osaka Police Hospital, Osaka, Japan, 12NHO Kure Medical Center /Chugoku Cancer Center, Kure, Japan, 13NHO Asahikawa Medical Center, Asahikawa, Japan, 14Nissei hospital, Sapporo, Japan, 15NHO Hokkaido Cancer Center, Sapporo, Japan, 16NHO Morioka Medical Center, Morioka, Japan, 17NHO Shimoshizu Hospital, Yotsukaido, Japan, 18NHO Ibarakihigashi Hospital, Ibaraki, Japan, 19NHO Yokohama Medical Center, Yokohama, Japan, 20National Hospital Organization Yokohama Medical Center, Yokohama, Japan, 21NHO Sagamihara Hospital, Sagamihara, Japan, 22NHO Disaster Medical Center, Tachikawa, Japan, 23NHO Shinshu Ueda Medical Center, Ueda, Japan, 24NHO Kanazawa Medical Center, Kanazawa, Japan, 25NHO Awara Hospital, Awara, Japan, 26NHO Osaka Toneyama Medical Center, Toyonaka, Japan, 27Japan Red Cross Society Tokushima Hospital, Komatsushima, Japan, 28NHO Okayama Medical Center, Okayama, Japan, 29NHO Hiroshima Nishi Medical Center, Otake, Japan, 30NHO Shikoku Cancer Center, Matsuyama, Japan, 31NHO Kyushu Cancer Center, Fukuoka, Japan, 32NHO Ureshino Medical Center, Ureshino, Japan, 33NHO Fukuoka Hospital, Fukuoka, Japan, 34NHO Nagasaki Medical Center, Omura, Japan, 35NHO Beppu Medical Center, Beppu, Japan, 36NHO Kumamoto Saishun Medical Center, Koshi, Japan, 37NHO Kumamoto Minami Hospital, Uki, Japan, 38NHO Miyakonojo Medical Center, Miyakonojo, Japan, 39NHO Kagoshima Medical Center, Kagoshima, Japan, 40Yokohama City University Medical Center, Yokohama, Japan, 41Yokohama Minami Kyosai Hospital, Yokohama, Japan, 42Department of Pathology Yokosuka Kyosai Hospital, Yokosuka, Japan, 43Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital / Tokyo Metropolitan Komagome Hospital, Tokyo, Japan, 44Tokyo Metropolitan Matsuzawa Hospital, Tokyo, Japan, 45Niigata Rheumatic Center, Shibata, Japan, 46Fuchu Hospital, Izumi, Japan, 47Sumitomo Hospital, Osaka, Japan, 48Nippon Life Hospital, Osaka, Japan, 49JCHO Hoshigaoka Medical Center, Hirakata, Japan, 50Kishiwada City Hospital, Kishiwada, Japan, 51Hyogo Prefectural Kakogawa Hospital, Kakogawa, Japan, 52Ako Central Hospital, Ako, Japan, 53Matsuyama Red Cross Hospital, Matsuyama, Japan, 54Osaka University, Suita, Japan, 55Fukuoka University, Fukuoka, Japan, 56Kurashiki University of Science and the Arts, Kurashiki, Japan, 57University of Occupational and Environmental Health, Kitakyushu, Japan, 58Hyogo Medical University, Nishinomiya, Japan, 59International University of Health and Welfare, Otawara City, Japan, 60NHO Tokyo National Hospital, Kiyose, Japan, 61NHO Tokyo National Hospital, Dallas, TX

    Background/Purpose: The largest multi-center collaborative study on lymphoproliferative disorders (LPD) in rheumatoid arthritis (RA) (RA-LPD) in Japan was conducted to characterize its clinical outcomes and…
  • Abstract Number: 1425 • ACR Convergence 2023

    Efficacy and Safety of Tofacitinib in an Open-Label, Long-Term Extension Study in Patients with Psoriatic Arthritis Who Received Adalimumab or Tofacitinib in a Phase 3 Randomized Controlled Study: A Post Hoc Analysis

    Dafna Gladman1, Peter Nash2, Philip J. Mease3, Oliver FitzGerald4, Karim R. Masri5, Stephanie Duench6 and Mary Jane Cadatal7, 1Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, 2School of Medicine, Griffith University, Brisbane, Australia, 3Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, 4Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, 5Pfizer Inc., Collegeville, PA, 6Pfizer Inc., New York, NY, 7Pfizer Inc., Manila, Philippines

    Background/Purpose: Patients (pts) with PsA and an inadequate response (IR) to conventional synthetic DMARDs are routinely treated with TNF inhibitors (TNFi).1,2 Intolerance/IR to TNFi may…
  • Abstract Number: 1428 • ACR Convergence 2023

    Guselkumab Provides Clinically Meaningful Improvents in Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Who Are Inadequate Responders to Tumour Necrosis Factor Inhibitors: Results Through One Year of a Phase 3b, Randomized, Controlled Study (COSMOS)

    Laure Gossec1, Xenofon Baraliakos2, James Galloway3, Lars Erik4, Vilija Oke5, Petros Sfikakis6, Emmanouil Rampakakis7, Mohamed Sharaf8, Frederic Lavie9 and Iain McInnes10, 1Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, 2Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 3King's College London, London, United Kingdom, 4Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, 5Karolinska Institutet, Stockholm, Sweden, 6National Kapodistrian University of Athens Medical School, Athens, Greece, 7JSS Medical Research, Saint-Laurent, QC, Canada, 8Immunology, Janssen MEA, Dubai, United Arab Emirates, 9The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, 10University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: In the Phase 3b COSMOS trial, guselkumab (GUS), a fully human IL-23p19 inhibitor (i), was associated with significantly greater improvements vs placebo (PBO) in…
  • Abstract Number: 1559 • ACR Convergence 2023

    Comparison of Treatment with Adalimumab, Infliximab and Certolizumab in Refractory Cystoid Macular Edema Due to Behçet Disease

    Nuria Barroso-Garcia1, Jose Luis Martin-Varillas2, Lara Sanchez-Bilbao3, Ivan Ferraz Amaro4, Vanesa Calvo Río5, Alfredo Adán6, Inés Hernanz-Rodriguez7, Emma Beltran-Catalan8, David Diaz-Valle9, Marisa Hernandez-Garfella10, Lucia Martinez-Costa11, Manuel Diaz-Llopis12, Jose M Herreras13, Olga Maiz-Alonso14, Ignacio Torre-Salaberri15, Antonio Atanes Sandoval16, Santos Insua-Vilariño17, Raquel Almodovar18, Patricia Fanlo-Mateo19, Juan Ramon De Dios20, Angel Garcia-Aparicio21, Sergio rodriguez-Montero22, Vega Jovani23, Patricia Moya24, Eva Peña Sainz-Pardo25, Jose Luis Hernandez26 and Ricardo Blanco27, 1Hospital Universitario Puerta del Mar, Cadiz, Spain, 2Hospital de Laredo, Laredo, Spain, 3Hospital Universitario Marques de Valdecilla, Santander, Spain, 4Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 5Valdecilla Hospital, Santander, Spain, 6Oftalmology, Hospital Clinic de Barcelona, Barcelona, Spain, 7Ophthalmology, Hospital Clinic de Barcelona, Barcelona, Spain, 8HOSPITAL DEL MAR, Barcelona, Spain, 9Hospital Clinico San Carlos, Madrid, Spain, 10Ophthalmology, Hospital Universitario General Valencia, Valencia, Spain, 11Ophthalmology, Hospital Universitario Doctor Peset, Valencia, Spain, 12Ophthalmology, Hospital Universitario La Fe, Valencia, Spain, 13Ophthalmology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain, 14University Hospital Donostia, San Sebastian, Spain, 15Hospital Universitario de Basurto, Bilbao, Spain, 16Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC)., A Coruña, Spain, 17Rheumatology, Hospital Universitario de Santiago de Compostela, Santiago Compostela, Spain, 18Alcorcón Foundation University Hospital, Madrid, Spain, 19Internal Medicine, Complejo Hospitalario Universitario de Navarra, Pamplona, Spain, 20Osakidetza, Vitoria, Spain, 21Hospital Universitario de Toledo, Toledo, Spain, 22Rheumatology, Hospital Universitario Virgen de Valme, Sevilla, Spain, 23Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain, 24Hospital de Santa Creu i Sant Pau, Barcelona, Spain, 25Pediatric, Hospital 12 de Octubre, Madrid, Spain, 26Rheumatology, Ophthalmology and Internal Medicine, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 27Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Cystoid macular edema (CME) is the leading cause of blindness in non-infectious uveitis. One of the most frequently associated conditions is Behçet's disease (BD)…
  • Abstract Number: 1666 • ACR Convergence 2023

    TNF-mediated Pulmonary Hypertension Is Marked by Aberrant Bone Morphogenic Protein (BMP) and Integrin/Basement Membrane Ligand-Receptor Signaling

    Javier Rangel-Moreno1, Maria de la Luz Garcia-Hernandez2, Qingfu Xu3 and Benjamin Korman1, 1University of Rochester, Rochester, NY, 2University of Rochester, West Henrietta, NY, 3University of Rochester Medical Center, Rochester, NY

    Background/Purpose: : We recently described TNF-transgenic mice as a novel model of pulmonary hypertension (PH) and have shown that they express altered endothelial and mesenchymal…
  • Abstract Number: 0016 • ACR Convergence 2023

    Role of TP53 in Inflammatory Reprogramming of Rheumatoid Arthritis Synovial Fibroblasts

    Anil Singh and Salahuddin Ahmed, Washington State university, Spokane, WA

    Background/Purpose: TP53, a tumor-suppressor protein known as the guardian of the genome, plays a critical role in regulating genomic stability and cellular function. When TP53…
  • Abstract Number: 1673 • ACR Convergence 2023

    Immunomodulatory Treatment and Autoimmune Patient Responses to COVID-19 Booster Shots: Results from the Covid-19 VaccinE Response in Rheumatology Patients (COVER) Study

    Amy S. Mudano1, Gary Cutter2, Ted R Mikuls3, Geoffrey Thiele4, Emily Holladay2, Kevin Withrop5, Mark Law4, Bart Hamilton4, Monique Bastidas6, Michael Zikry6, Kelly Chun6, Michael George7 and Jeffrey Curtis2, 1Illumination Health, Hoover, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 4University of Nebraska Medical Center, Omaha, NE, 5Oregon Health & Science University, Schools of Medicine and Public Health,, Portland, OR, 6Labcorp, Calabasas, CA, 7University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Given an increased risk of COVID-19 in patients with autoimmune conditions, we must better understand the immunogenicity and safety of SARS-CoV-2 vaccines in people…
  • Abstract Number: 0370 • ACR Convergence 2023

    Clinical Disease Manifestations Associated with TNF Inhibitor Non-Response in Juvenile Spondyloarthritis

    Melissa Oliver1, Kelly Mosesso2, Pamela F. Weiss3, Robert Colbert4, Matthew Stoll5 and Hemalatha Srinivasalu6, 1Indiana University, Indianapolis, IN, 2Indiana University School of Medicine, Indianapolis, IN, 3Children's Hospital of Philadelphia, Philadelphia, PA, 4NIH/NIAMS, Bethesda, MD, 5University of Alabama at Birmingham, Birmingham, AL, 6Children's National Hospital, Washington, DC

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are effective in children with juvenile spondyloarthritis (JSpA) and generally represent the first-line choice for biologic therapy. However, not…
  • Abstract Number: 1725 • ACR Convergence 2023

    Distinct Perivascular and Intravascular Lymphatic Mast Cells and Their Role in Lymphatic Clearance, Joint Inflammation, and Bone Erosion in the TNF-Transgenic Murine Arthritis Model

    Yue Peng1, H. Mark Kenney2, Karen Bentley3, Lianping Xing4, Christopher T Ritchlin5 and Edward Schwarz3, 1University of Rochester Medical Center, Rochester, NY, 2University of Rochester School of Medicine and Dentistry, Henrietta, NY, 3University of Rochester, Rochester, NY, 4University of Rochester Medical Center, Webster, NY, 5University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY

    Background/Purpose: Inflammatory-erosive arthritis is exacerbated by lymphatic dysfunction (1), and mast cells (MCs) regulate lymphatic vessel contractions via release of inflammatory and vasoactive mediators (2).…
  • Abstract Number: 0404 • ACR Convergence 2023

    Persistent Pain and Its Predictors After Start of Anti-TNF Therapy in Rheumatoid Arthritis – Is Line of Treatment Linked to Different Pain Patterns?

    Carmen Roseman, Johan Karlsson Wallman, Jon Einarsson, Elisabeth Mogard, Elisabet Lindqvist, Meliha Kapetanovic and Tor Olofsson, Lund University and Skåne University Hospital, Lund, Sweden

    Background/Purpose: Persisting pain with or without inflammation control is a common and debilitating symptom in rheumatoid arthritis (RA). Concerns have been raised that patients with…
  • Abstract Number: 1767 • ACR Convergence 2023

    TNF-α Utilizes the TWEAK/Fn-14 Axis in Human Rheumatoid Arthritis Synovial Fibroblasts to Induce Inflammation

    Farheen Sultan Shaikh1, Anil Singh1, Paul Panipinto2 and Salahuddin Ahmed1, 1Washington State University, Spokane, WA, 2Washington State University College of Pharmaceutical Science and Molecular Medicine, Spokane, WA

    Background/Purpose: Tumor necrosis factor-alpha (TNF)-α is a proinflammatory cytokine in rheumatoid arthritis that transduces intracellular signal transduction pathways through specific receptors, TNF-R1, and TNF-R2. The…
  • Abstract Number: 0429 • ACR Convergence 2023

    Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Rheumatoid Arthritis: Results from a Randomized Phase 3 Study

    Peter C. Taylor1, David Walsh2, Tsutomu Takeuchi3, Bruno Fautrel4, Janet Pope5, Andrew Garrison6, Yanna Song6, Sara K. Penn6, Ralph Lippe7, Diane Caballero8 and Arthur Kavanaugh9, 1Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2University of Nottingham, Nottingham, United Kingdom, 3Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, 4Sorbonne Université APHP, Paris, France, 5University of Western Ontario, London, ON, Canada, 6AbbVie, Inc., North Chicago, IL, 7AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, 8AbbVie, Inc., Chicago, IL, 9University of California San Diego, School of Medicine, Riverside, CA

    Background/Purpose: Rapid and sustained pain control is an important goal for patients (pts) with rheumatoid arthritis (RA). Control of inflammation in RA does not always…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology